Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | Comparability of next generation gene panel assays in CLL

Richard Rosenquist • 23 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia

Richard Rosenquist Brandell, MD, of Karolinska Institute, Solna, Stockholm, reviews the comparability of various next-generation gene panel assays in identifying mutations in chronic lymphocytic leukemia (CLL) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Richard Rosenquist

The advancements and remaining challenges in precision medicine for CLL
2:09
The advancements and remaining challenges in precision medicine for CLL
Richard Rosenquist • 27 Sep 2024
Recommendations for biomarker analysis in CLL: updates from ERIC 2024
5:40
Recommendations for biomarker analysis in CLL: updates from ERIC 2024
Richard Rosenquist • 27 Sep 2024
The impact of IGHV mutational status in treatment decisions in CLL
1:50
The impact of IGHV mutational status in treatment decisions in CLL
Richard Rosenquist • 7 Oct 2022
Common genetic tests in CLL & when these tests should be performed
1:26
Common genetic tests in CLL & when these tests should be performed
Richard Rosenquist • 7 Oct 2022

Related Videos

cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
1:10
cAMeLot-2: Phase III trial of bleximenib + venetoclax + azacitidine in AML with KMT2A/NPM1 mutations
Richard Rosenquist • 24 Nov 2025
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
1:16
Single-agent SC blinatumomab in R/R B-ALL: Phase I/II efficacy results with extended follow-up
Richard Rosenquist • 24 Nov 2025
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Richard Rosenquist • 6 Dec 2025
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
2:20
Bexobrutideg in CLL and approaching the sequencing of BTK degraders and inhibitors
Richard Rosenquist • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals